Last reviewed · How we verify
G-004
G-004 is a small molecule that targets the SGLT2 receptor.
G-004 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.
At a glance
| Generic name | G-004 |
|---|---|
| Sponsor | Hvivo |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 2 |
Mechanism of action
By inhibiting SGLT2, G-004 reduces glucose reabsorption in the kidneys, thereby lowering blood glucose levels. This makes it a potential treatment for type 2 diabetes.
Approved indications
- Type 2 diabetes
Common side effects
- Increased risk of diabetic ketoacidosis
Key clinical trials
- Study Examining PrEP-001 in Healthy Subjects (PHASE2)
- Study Examining PrEP-001 in Subjects With Asthma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- G-004 CI brief — competitive landscape report
- G-004 updates RSS · CI watch RSS
- Hvivo portfolio CI